A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
Last Updated March 7, 2025
Want to learn how to participate in this trial?
74765340RPG2001
OVERVIEW
-
Sexes Eligible for Study
male -
Age
years -
Phase
phase 2 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
CONDITIONS
- X-Linked Retinitis Pigmentosa
ELIGIBILITY
Inclusion Criteria:
* Have been treated with AAV5-hRKp.RPGR in study MGT009 and have completed or is currently enrolled in Study MGT010
* Must sign an informed consent form indicating that they understand the purpose and procedures of the study and is willing to participate in th
DETAILS
LOCATIONS
| Country (1) | City or Province (2) | Status |
| United States | Ann Arbor University of Michigan Kellogg Eye Center |
RECRUITING
|
| United States | Boston Massachusetts Eye and Ear Infirmary |
RECRUITING
|
42.27756, -83.74088
42.35843, -71.05977
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.